Background and Objectives: The enteric form of omeprazole is one of the most commonly prescribed medications. Similarly to Europe, Kazakhstan relies on the localization of pharmaceutical drug production as one of its primary strategies to ensure that its population has access to affordable and good-quality medicines. This study comprehensively describes the technologically available development of bioequivalent delayed-release omeprazole. Materials and Methods: Various regimes and technological parameters were tested on laboratory- and production-scale equipment to establish a technical process where a functional and gastro-protective layer is essential. According to the ICH guidance on stability testing and Kazakhstan local rules, stability studies were conducted under conditions appropriate for climate zone II. The comparison of the rate and extent of absorption with subsequent assessment of the bioequivalence of the generic and reference drugs after a single dose of each drug at a dose of 40 mg was performed. Results: The quantitative and qualitative composition and technology of producing a new generic enteric form of omeprazole in capsules were developed and implemented at the manufacturing site of solid forms. Dissolution profiles in media with pH 1.2 and 6.8 were proven. During the accelerated six-month and long-term twelve-month studies, the developed formulation in both packaging materials at each control point passed the average weight and mass uniformity test, dissolution test, acid-resistance stage test, buffer stage test, impurity assay, and microbiological purity test and met all the specification criteria. A bioequivalence study in 24 healthy volunteers compared against the innovative drug showed the bioequivalency of the new generic system. The obtained values from the test and reference products were 1321 ± 249.0 ng/mL and 1274 ± 233 ng/mL for Cmax, 4521 ± 841 ng·h /mL and 4371 ± 695 ng·h /mL for AUC0-t, and 4636 ± 814 ng·h /mL and 4502 ± 640 ng·h /mL for AUC0-∞. Conclusions: Using affordable technologies, a bioequivalent generic delayed-release formulation of 20 and 40 mg omeprazole has been developed.

Department of Pharmaceutical Technology Faculty of Pharmacy Masaryk University 612 00 Brno Czech Republic

Viva Pharm Almaty 050060 Kazakhstan

Zobrazit více v PubMed

Dekhnich N.N. Proton pump inhibitors in the treatment of acid-dependent diseases. Bull. Smolensk. State Med. Acad. 2011;1:21–24.

Lazebnik L.B., Lee E.D., Mikheeva O.M. The use of proton pump inhibitors for the treatment of acid-related diseases. Arch. Intern. Med. 2013;3:56.

Product Monograph Losec® (Omeprazole Delayed Release Capsules) 20 mg Omeprazole H+, K+-ATPase Inhibitor. AstraZeneca Canada Inc.; Mississauga, ON, Canada: 2017.

Junggren U.K., Sjöstrand S.E. Substituted Pyridylsulfinylbenzimidazoles Having Gastric Acid Secretion Properties, Pharmaceutical Preparations Containing Same, and Intermediates for Their Preparation. Patent No. EP0005129A1. 1979 October 31;

Trends in Drug Patenting—Case Studies: The Cases: 5. Omeprazole. apps.who.int. Oct 2, 2010. [(accessed on 22 August 2019)]. Available online: http://apps.who.int/medicinedocs/en/d/Js4915e/2.5.html.

Leading chemical substances dispensed in England in 2022, by number of items. [(accessed on 25 February 2024)]. Available online: https://www.statista.com/statistics/378445/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england//

Omeprazole Drug Usage Statistics, United States, 2013–2021. [(accessed on 25 February 2024)]. Available online: https://clincalc.com/DrugStats/Drugs/Omeprazole//

Kumisbek G.K., David V. Relevance of Application and Market Review of Proton Pump Inhibitors and Omeprazole//Natural Sciences and Medicine: Theory and Practice: Collection. Art. by Mother XL-XLI International Scientific-Practical Conf. 11–12. SibAK; Novosibirsk, Russia: 2021. pp. 42–48.

RSE on REM “National Center for Expertise of Medicines and Medical Devices” of the Committee for Medical and Pharmaceutical Control of the Ministry of Health of the Republic of Kazakhstan Home Page. [(accessed on 7 December 2021)]. Available online: http://register.ndda.kz/category/search_prep.

Bai M., Chen S., Xin W., Wu H. Patent No. CN102119927B. Enteric-Coated Pellet Preparation of Proton Pump Inhibitor and Preparation Method Thereof. 2012 December 26; CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.: Shijiazhuang, China.

Chen J.-R. Preparation of Enteric Pharmaceutical Dosage Forms for Omerprazole and Lansoprazole. Patent No. US 6,726,927 B2. 2004 April 27; Sage Pharmaceuticals, Inc.: Shreveport, LA, USA, 2012.

Bengtsson I.S., Lovgren K.I. Pharmaceutical Formulation of Omeprazole. Patent No5,690,960. US Patent. 1997 November 25; Astra Aktiebolag: Sodertalje, Sweden.

United States Pharmacopeia . USP Monographs, Omeprazole Delayed-Release Capsules. USP-NF (United States Pharmacopeia); Rockville, MD, USA: 2023. Doc ID: GUID-71E87DD7-0164-42C0-8027-A9211B069968_1_en-US. DOI

ICH Topic Q 1 A (R2) Stability Testing of New Drug Substances and Products. Note for Guidance on Stability Testing: Stability Testing of New Drug Substances and Products (CPMP/ICH/2736/99) The ICH Official Website. [(accessed on 23 November 2023)]. Available online: https://www.ich.org/page/quality-guidelines.

On Approval of the Rules for Conducting Stability Studies by the Manufacturer of a Medicinal Product, Establishing a Shelf Life and Re-Monitoring of Medicinal Products Order of the Minister of Health of the Republic of Kazakhstan. Dated 28 October 2020. No. KR DSM-165/2020. Registered with the Ministry of Justice of the Republic of Kazakhstan on 30 October 2020. No. 21545. [(accessed on 23 November 2023)]. Available online: https://adilet.zan.kz/rus/index/docs.

Rules for Conducting Bioequivalence Studies of Medicinal Products within the Framework of the Eurasian Economic Union. Council of the Eurasian Economic Commission; Moscow, Russia: 2016. No. 85.

Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER), US Government Printing Office; Washington, DC, USA: 2018.

Guideline on Bioanalytical Method Validation. European Medicines Agency, Committee for Medicinal Products for Human Use (EMEA); Amsterdam, The Netherlands: 2011. EMEA/CHMP/EWP/192217/2009.

Mironov N. Guidelines for Examination of Medicinal Products. Volume 1 Federal State Budgetary Institution “NTsESMP”; Moscow, Russia: 2014.

Šalandová J., Franc A., Hofmann J., Dumicic A., Kukačková L., Červená T., Beránek J., Srbek J., Repický A., Vladovičová B., et al. The effect of the composition of a fixed dose combination on bioequivalence results. Int. J. Pharm. 2018;546:235–246. doi: 10.1016/j.ijpharm.2018.05.030. PubMed DOI

He W., Fan L.-F., Du Q., Xiang B., Li C.-L., Bai M., Chang Y.-Z., Cao D.-Y. Design and in Vitro/in Vivo Evaluation of Multi-layer Film Coated Pellets for Omeprazole. Chem. Pharm. Bull. 2009;57:122–128. doi: 10.1248/cpb.57.122. PubMed DOI

Joti J.J., Nahar K., Hasan A., Azad M.A., Ullah M.A., Islam S.M., Hasnat A. Bioequivalence and Pharmacokinetic Study of Two Different Omeprazole Capsule Formulations in Healthy Bangladeshi Volunteers. Arzneimittelforschung. 2009;59:171–175. doi: 10.1055/s-0031-1296382. PubMed DOI

Mansouri K., Ghozal M., Behloul S., Adda Abbou L., Makhlouf A., Nekhoul K., Hadjaz I., Mansouri M.B. Bioequivalence of Two Brands of Omeprazole 20 mg Gastro-Resistant Capsules in 18 Healthy Algerian Volunteers: A Pilot Study. J. Pharm. Pharmacol. 2017;5:877–884. doi: 10.17265/2328-2150/2017.12.005. DOI

Guideline on the Investigation of Bioequivalence. European Medicines Agency, Committee for Medicinal Products for Human Use (EMEA); Amsterdam, The Netherlands: 2011. EMEA/CPMP/EWP/QWP/1401/98.

Chow S.C., Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker Inc.; New York, NY, USA: 1992.

Hauschke D., Kieser M., Diletti E., Burke M. Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Stat. Med. 1999;18:93–105. doi: 10.1002/(SICI)1097-0258(19990115)18:1<93::AID-SIM992>3.0.CO;2-8. PubMed DOI

Berger R.L., Hsu J.C. Bioequivalence Trials, Intersection-Union Tests and Confidence Sets. Stat. Sci. 1996;11:283–319. doi: 10.1214/ss/1032280304. DOI